Drugs in MeSH Category Purinergic P1 Receptor Agonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	ADENOSINE	adenosine	SOLUTION;INTRAVENOUS	090450-002	Oct 2, 2014	AP	RX	No	No
Meitheal	ADENOSINE	adenosine	SOLUTION;INTRAVENOUS	077425-001	Aug 29, 2013	AP	RX	No	Yes
Teva Pharms Usa	ADENOSINE	adenosine	INJECTABLE;INJECTION	076564-001	Jun 16, 2004		DISCN	No	No
Hikma	ADENOSINE	adenosine	INJECTABLE;INJECTION	076404-001	Jun 16, 2004	AP	RX	No	No
Teva Pharms Usa	ADENOSINE	adenosine	INJECTABLE;INJECTION	078676-001	Jul 31, 2008		DISCN	No	No

Purinergic P1 Receptor Agonists Market Analysis and Financial Projection

The market for Purinergic P1 Receptor Agonists is evolving rapidly, driven by their therapeutic potential in treating conditions like cardiovascular diseases, cancer, and neurodegenerative disorders. Here's an analysis of the market dynamics and patent landscape:

---

Market Dynamics

Current Market Size and Growth

• The Adenosine Receptor A3 (A3AR) market, a subset of P1 agonists, was valued at $1.2 billion in 2024 and is projected to reach $2.5 billion by 2033, growing at a 9.1% CAGR[10].
• Growth is fueled by rising demand for targeted therapies, particularly for cancer, inflammation, and cardiovascular diseases. For example, Can-Fite BioPharma’s A3AR agonist Namodenoson is in advanced trials for liver cancer and metabolic disorders[4].

Key Drivers

1. Chronic Disease Burden: Cardiovascular diseases (32% of global deaths) and cancer (global drug spending >$145 billion in 2020) drive demand for P1 agonists[10][12].
2. Biotechnology Advances: Innovations in drug design, such as subtype-specific agonists (e.g., A2A for myocardial imaging[5]), enhance therapeutic precision.
3. Personalized Medicine: Tailored therapies leveraging genetic profiles are accelerating R&D, with over 20 P1 receptor-targeting compounds in clinical trials[12].

Challenges

• High Development Costs: Average drug development costs range from $1.3–$2.6 billion, including clinical trials[10].
• Regulatory Hurdles: Stringent FDA/EMA requirements delay approvals, though two P1 agonists (adenosine and regadenoson) are already FDA-approved[12].

---

Patent Landscape

Key Trends

• Patent Thickets: Device and formulation patents dominate. For instance, 107 device patents are listed for GLP-1 agonists (a related class), delaying generic competition through complex litigation[2].
• Subtype-Specific Claims:
  • A2A agonists: Patent US-8106029-B2 covers regadenoson for myocardial imaging[5].
  • A3 agonists: WO2015080940A1 protects novel compounds targeting inflammatory and autoimmune diseases[14].

Regional Distribution

• North America holds 40% market share due to strong R&D investments[4].
• Asia-Pacific is the fastest-growing region, driven by healthcare expansion in China and India[10].

---

Competitive Landscape

Company	Focus	Pipeline Highlights
Can-Fite BioPharma	A3AR agonists	Namodenoson (Phase III for liver cancer)
Huons Global	A3AR modulators	Diversified biologics for metabolic disorders[4]
Gilead Sciences	A2A agonists	Regadenoson (FDA-approved for cardiac imaging)[5]

---

Future Outlook

• Emerging Applications: Research into P1 receptors’ role in neuroprotection (e.g., ischemic stroke[13]) and chronic pain could unlock new markets[9].
• Collaborative R&D: Partnerships between academia and biotech firms are critical to overcoming cost and regulatory barriers[4][12].

Highlight: "Targeting adenosine receptors offers transformative potential in precision medicine, but requires navigating patent complexities and high development risks." [12]

In summary, while the Purinergic P1 Receptor Agonist market faces challenges like high costs and patent disputes, its growth trajectory remains strong due to unmet medical needs and therapeutic innovation.

References

1. https://www.futuremarketinsights.com/reports/glp-1-receptor-agonist-market
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10845039/
3. https://meshb.nlm.nih.gov/record/ui?ui=D058906
4. https://github.com/rocicbenton/Market-Research-Report-List-1/blob/main/adenosine-receptor-a3-market.md
5. https://pubchem.ncbi.nlm.nih.gov/patent/US8106029
6. https://boa.unimib.it/retrieve/e39773b5-030f-35a3-e053-3a05fe0aac26/DPhG2018_ConferenceBook_Final_27-09-2018.pdf
7. https://www.gminsights.com/industry-analysis/glp-1-receptor-agonist-market
8. https://patents.google.com/patent/WO2008074821A1/en
9. https://en.wikipedia.org/wiki/Purinergic_receptor
10. https://www.verifiedmarketreports.com/product/adenosine-receptor-a3-market/
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC3481036/
12. https://pubmed.ncbi.nlm.nih.gov/31333097/
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC9984595/
14. https://patents.google.com/patent/WO2015080940A1/en